...Wen-Lin Zhang; Bo-Shen Lin; Yue-Yue Li; Yu-Ming Ding; Zhong-Xue Han; Rui Ji Introduction: Vonoprazan, a novel potassium-competitive acid blocker, has a strong acid suppression effect and potent efficacy in acid-associated diseases, including Helicobacter pylori eradication. We performed...

... erosive esophagitis who confirmed mucosal healing by endoscopy after initial treatment with vonoprazan (VPZ) were enrolled. The patients continued subsequent treatment of their choice: maintenance therapy with VPZ 10 mg ( n = 15), on-demand therapy with VPZ 20 mg ( n = 19), or no medication ( n = 17...

... discontinuation in the above 92 patients were a proton pump inhibitor (PPI) and vonoprazan (VPZ, a potassium ion competitive acid blocker). Since PPI and VPZ were administered to about the same number of patients, though incidentally, we additionally examined the relationship between patient background factors...

... is potentially induced by H. pylori treatment. Summary: Based on current international guidelines and a network meta-analysis comparing the effects of various treatment regimens, nonbismuth quadruple therapies for 10–14 days and vonoprazan-based triple therapy for 7 days are the currently recommended H. pylori...

...Tsugitaka Ishida; Osamu Dohi; Shinya Yamada; Takeshi Yasuda; Nobuhisa Yamada; Akira Tomie; Toshifumi Tsuji; Yusuke Horii; Atsushi Majima; Ryusuke Horie; Akifumi Fukui; Keika Zen; Naoya Tomatsuri; Nobuaki Yagi; Yuji Naito; Yoshito Itoh Background: Vonoprazan (VPZ) has the potential to prevent...

...Shohei Hamada; Eikichi Ihara; Hiroko Ikeda; Kazumasa Muta; Haruei Ogino; Takatoshi Chinen; Yoshimasa Tanaka; Yoshihiro Ogawa Introduction: The newly developed vonoprazan (a potassium-competitive acid blocker) has a greater ability to suppress gastric acid production than convention proton pump...

...Takahisa Furuta; Mihoko Yamade; Takuma Kagami; Takahiro Uotani; Takahiro Suzuki; Tomohiro Higuchi; Shinya Tani; Yasushi Hamaya; Moriya Iwaizumi; Hiroaki Miyajima; Kazuo Umemura; Satoshi Osawa; Ken Sugimoto Backgrounds/Aims: Vonoprazan (VPZ) is the first clinically available potassium competitive...

.... Treatments included a conventional proton pump inhibitor (PPI) blister-packaged drug containing lansoprazole or rabeprazole with clarithromycin (CAM) and amoxicillin (AC), vonoprazan (VPZ) with CAM and AC in a separate tablet, or a VPZ blister-packaged drug (VONOSAP) containing VPZ with CAM and AC, with all...

...Hideki Mizuno; Michiko Nishino; Kazutoshi Yamada; Shinji Kamiyamamoto; Yoshinobu Hinoue Aims: We aimed to evaluate the efficacy of vonoprazan (VPZ) as maintenance therapy for healed reflux esophagitis (RE). Methods: We enrolled 74 patients diagnosed with RE with frequency scale for the symptoms...

... to in the content or advertisements. 2018 Non-erosive reflux disease Potassium-competitive acid blocker-resistant Vonoprazan Impedance-pH monitoring Helicobacter pylori The clinical practice guidelines for gastroesophageal reflux disease (GERD) established by the Japanese Society...

...Mariko Umezawa; Noriyuki Kawami; Shintaro Hoshino; Yoshimasa Hoshikawa; Eriko Koizumi; Nana Takenouchi; Yuriko Hanada; Mitsuru Kaise; Katsuhiko Iwakiri Background: The study aimed to evaluate the efficacy of on-demand therapy using 20-mg vonoprazan for mild reflux esophagitis (RE). Methods...

... reflux esophagitis. On the other hand, several adverse reactions, such as an increase in the blood gastrin level, have been reported. The aim of the present study was to examine the increase in the blood gastrin level due to the long-term administration of conventional PPIs compared with vonoprazan...

... demonstrated that vonoprazan-based Helicobacter pylori eradication therapy achieved higher eradication rate compared with lansoprazole. However, there is no study that evaluated the efficacy of vonoprazan in a large sample in real world. We investigated the eradication rate and safety of vonoprazan-based...

.... To heal ESD-induced ulcers, we commonly prescribe proton pump inhibitors (PPIs). Vonoprazan is our new choice, which is reported to have a stronger and longer acid inhibitory effect than existing PPIs. Here, we aimed to evaluate the efficacy of vonoprazan for healing ESD-induced ulcers compared...

...Hiroshi Yamashita; Atsushi Kanamori; Chise Kano; Hiroki Hashimura; Kei Matsumoto; Masahiro Tsujimae; Tetsuya Yoshizaki; Kenji Momose; Daisuke Obata; Takaaki Eguchi; Mikio Fujita; Akihiko Okada Background/Aim: The effects of vonoprazan and proton pump inhibitors (PPIs) in patients with reflux...

.... The acid-inhibitory effect of vonoprazan, a novel potassium-competitive acid blocker (P-CAB), is significantly greater when compared to the effect of PPIs. We investigated the efficacy of vonoprazan treatment for PPI-refractory GERD and factors associated with P-CAB non-response. Methods: We enrolled 277...

...Shintaro Hoshino; Noriyuki Kawami; Nana Takenouchi; Mariko Umezawa; Yuriko Hanada; Yoshimasa Hoshikawa; Tetsuro Kawagoe; Hirohito Sano; Yoshio Hoshihara; Tsutomu Nomura; Katsuhiko Iwakiri Background: Vonoprazan (VPZ) is a novel potassium-competitive acid blocker that may be clinically beneficial...

... inhibition during treatment is important to eradicate these bacteria successfully. A new potassium-competitive acid blocker, vonoprazan (VPZ), has been shown to achieve high eradication rates in a previous randomized controlled trial. Objective: To determine the efficacy of VPZ for H. pylori eradication...